<DOC>
<DOCNO>EP-0656348</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Aceric acid derivatives as medicaments
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C27164	C07C25900	A61K314418	C07C27106	C07D30768	A61K3100	A61P702	C07D21378	C07D40112	A61K31445	C07D21146	A61P1900	A61K31472	A61K3134	A61K31341	A61K3127	C07C25100	C07D20712	C07D21381	C07C25918	A61K31472	C07C25148	A61K3124	C07D26714	C07D41312	A61K3122	C07C32342	C07F924	C07D27107	C07D41302	C07D27100	A61K31445	A61K31341	C07D20700	C07C32300	A61K3119	C07D21382	A61K3100	C07C23732	C07C25718	A61P1900	C07F900	C07C25124	C07C33304	C07D21194	C07C23700	C07D26700	A61P700	C07D30700	C07C25700	C07D30912	C07D21702	A61K31395	C07D21100	A61K31185	C07C33300	C07D21700	C07D30900	A61K3121	A61K3134	C07D21300	A61K3147	A61K31395	A61P700	A61K314418	C07C32350	C07C27100	C07D21134	C07D40100	C07D41300	A61K3147	C07D21120	C07D21100	C07C27162	C07D27106	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	C07C	A61K	C07C	C07D	A61K	A61P	C07D	C07D	A61K	C07D	A61P	A61K	A61K	A61K	A61K	C07C	C07D	C07D	C07C	A61K	C07C	A61K	C07D	C07D	A61K	C07C	C07F	C07D	C07D	C07D	A61K	A61K	C07D	C07C	A61K	C07D	A61K	C07C	C07C	A61P	C07F	C07C	C07C	C07D	C07C	C07D	A61P	C07D	C07C	C07D	C07D	A61K	C07D	A61K	C07C	C07D	C07D	A61K	A61K	C07D	A61K	A61K	A61P	A61K	C07C	C07C	C07D	C07D	C07D	A61K	C07D	C07D	C07C	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C271	C07C259	A61K31	C07C271	C07D307	A61K31	A61P7	C07D213	C07D401	A61K31	C07D211	A61P19	A61K31	A61K31	A61K31	A61K31	C07C251	C07D207	C07D213	C07C259	A61K31	C07C251	A61K31	C07D267	C07D413	A61K31	C07C323	C07F9	C07D271	C07D413	C07D271	A61K31	A61K31	C07D207	C07C323	A61K31	C07D213	A61K31	C07C237	C07C257	A61P19	C07F9	C07C251	C07C333	C07D211	C07C237	C07D267	A61P7	C07D307	C07C257	C07D309	C07D217	A61K31	C07D211	A61K31	C07C333	C07D217	C07D309	A61K31	A61K31	C07D213	A61K31	A61K31	A61P7	A61K31	C07C323	C07C271	C07D211	C07D401	C07D413	A61K31	C07D211	C07D211	C07C271	C07D271	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Acetic acid derivatives of the formula 
<
IMAGE
>
 in which L, M, Q and T have the meaning stated in the description, can be used for the treatment or prophylaxis of diseases caused by the binding of adhesive proteins to blood platelets, and by aggregation of blood platelets and cell-cell adhesion. They are prepared by eliminating protective groups in corresponding protected compounds or by converting the cyano group into the amidino group in corresponding nitriles.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Acetic acid derivatives of the formula


wherein

L
is a group of formulae L
1
 to L
5
:


in which a carbonyl group present in the L group and/or between the L and
M groups which is not bonded in the form of an amide can also be present

as an oxime,
A
is a group of formulae A
1
 to A
4
: 

E
1
 and E
2
are H, lower-alkyl, OH, lower-alkoxy, lower-alkoxy-lower-alkyl, carboxy-lower-alkyl,
P(O)(O-lower-alkyl)
2
, C(O)OR
1
, OC(O)R
1
, OC(O)OR
1
 or
C(O)SR
1
, with at least one of E
1
 and E
2
 being H, or
E' and E
2
together with the N atoms to which they are attached are a (5,5-dimethyl or
5-oxo)-4,5-dihydro-1,2,4-oxadiazol-3-yl group,
R
1
is lower-alkoxy-lower-alkyl, lower-alkyl, lower-alkyl substituted by OH,
COOH, lower-alkoxycarbonyl, lower-alkanoyloxy, lower-alkenoyloxy,

benzoyloxy optionally substituted (by lower-alkanoyloxy) or lower-alkyl-CONH,
or phenyl optionally substituted (by halogen or lower-alkoxy) and

optionally bonded via lower-alkylene, or cycloalkyl optionally interupted by
O,
one of X and Y
is CH and the other is CH, C-lower-alkyl, C-lower-alkoxy or N,
D
is a group (CH2)
s
 or (CH
2
)
t
O,
s
is 1 to 4,
m and n
are 0 to 5 and
t
is 0 to 3, but m + n is 1 to 5 and each of m + t and n + t is at least 1, 
p and q
are 0 to 5, but p + q is 2 to 5,
W
1
is CH
2
, lower alkyl-CH, lower-alkyl-OC(O)CH, NH, lower-alkyl-N or
lower-alkoxy-lower-alkyl-N,
W
2
is O, NH, acyl-N or lower-alkyl-OC(O)-N,
G
is H or lower-alkyl optionally substituted by OH, SH, CONH
2
, CONH-lower-alkyl,
lower-alkylthio, aryl, NH
2
, NH-R
a
, N(R
a
,R
b
) or OR
a
, with R
a

and R
b
 being lower-alkyl, lower-alkoxy-lower-alkyl, acyl or lower-alkoxycarbonyl,
M
is 1,4-piperidinylene bonded via the N atom to the keto group or 1,4-phenylene
optionally substituted by lower-alkyl, lower-alkoxy, OCH
2
COOH
or OCH
2
COO-lower-alkyl,
Q
is O, CH
2
, NH, acyl-N or lower-alkyl OC(O)N,
T
is NH
2
, NH-lower-alkyl, NH-lower-alkyl-COOH, NH-lower-alkyl-COO-lower-alkyl,
lower-alkoxy or lower-alkenyloxy substituted by lower-alkoxy,

COOH, COO-lower-alkyl, lower-alkyl-COO or lower-alkyl-OCOO, or a
group OT',
T'
is H, lower-alkyl, phenyl or pyridyl optionally bonded via lower-alkylene or
cycloalkyl optionally bonded via lower-alkylene and optionally interrupted

by O, NH or NCOO-lower-alkyl, with the provisos that
a)
T'
is different from H, lower-alkyl and phenyl-lower-alkyl where
L
is a group of the formula

A
is a group of the formula

one of E
1
 and E
2
is hydrogen and the other is hydrogen, tert-butoxycarbonyl or
benzyloxycarbonyl,
one of X and Y
is CH and the other is CH or N and
W
1
is NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N,
G
has the above significance,
M
is 1,4-piperidinylene bonded via the N atom to the keto group and
Q
is O, and
b)
T'
is different from H, lower-alkyl, phenyl and phenyl-lower-alkyl where
L
is a group of formula L
11
, L
31
 or L
41
;

A
is a group of formula A
1
one of E
1
 and E
2
is hydrogen and the other is hydrogen, tert-butoxycarbonyl or
benzyloxycarbonyl,
one of X and Y
is CH and the other is CH, C-lower-alkyl, C-lower-alkoxy or N, 
R
o
 and G
o
are H or lower-alkyl,
W
4
is C=O or C=NOH,
M
is 1,4-phenylene optionally substituted by lower-alkyl, lower-alkoxy,
OCH
2
COOH or OCH
2
COO-lower-alkyl and
Q
is O, CH
2
 or NH,
c)
A
can only be a group of formula A
3
 when L is a group of formula L
1
 and
M is 1,4-phenylene, and
d)
G
Is not hydrogen when L is a group of formula L
1
 and A is a group of
formula A
3
 or A
4
,

as well as hydrates or solvates and physiologically usable salts thereof, whereby 'lower'
denotes straight-chain or branched groups with 1 to 6 C atoms.
Compounds according to claim 1, wherein L is a group of the formula

A
is a group A
1
 , A
2
 or A
30
:

one of E
1
 and E
2
is H and the other is H, lower-alkyl, OH, lower-alkoxy, lower-alkoxy-lower-alkyl,
carboxy-lower-alkyl, PO(O-lower-alkyl)
2
, C(O)OR
1
 or
OC(O)OR
1
, 
R
1
is lower-alkoxy-lower-alkyl, lower-alkyl, lower-alkyl substituted by OH,
COOH or lower-alkanoyloxy, or phenyl optionally substituted and optionally

bonded via lower-alkylene, or cycloalkyl optionally interrupted by O,
one of X and Y
is CH and the other is CH or N,
m and n
are 0 to 5 and t is 0 to 3, but m + n is 1 to 5 and each of m + t and n + t
is at least 1,
W
1
is CH
2
, lower-alkyl-OCOCH, NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N,
G and M
have the same significance as in claim 1,
Q
is oxygen,
T
is a group OT'' and
T''
is H, lower-alkyl, lower-alkoxy-lower-alkyl or cycloalkyl optionally bonded
via lower-alkylene and optionally interrupted by O, with the provisos that
a)
T''
is different from H, lower-alkyl and phenyl-lower-alkyl where
A
is a group of the formula

E
1
 and E
2
are hydrogen, tert-butoxycarbonyl or benzyloxycarbonyl,
X, Y, G and Q
have the above significance,
W
1
is NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N and
M
is 1,4-piperidinylene bonded via the N atom to the keto group, and
b)
T''
is different from H, lower-alkyl, phenyl and phenyl-lower-alkyl where 
L
is a group of formula L
11
:

A
is a group of the formula

E
1
 and E
2
are hydrogen, tert-butoxycarbonyl or benzyloxycarbonyl,
X, Y and Q
have the above significance,
R
o
 and G
o
are H or lower-alkyl and
M
is 1,4-phenylene optionally substituted by lower-alkyl, lower-alkoxy,
OCH
2
COOH or OCH
2
COO-lower-alkyl,
c)
A
can only be a group of formula A
30
 when M is 1,4-phenylene,

and physiologically usable salts thereof.
Acetic acid derivatives according to claim 1, wherein L is a group L
1
 in
which A is a group A
1
, namely of the formula

wherein E
1
, E
2
, X, Y, W
1
, G, M, Q and T have the same significance as in claim 1.
Acetic acid derivatives according to claim 1 or 3, wherein one of E
1
 and E
2
 is
H and the other is H, OH, C(O)OR
1
 or OC(O)OR
1
. 
Acetic acid derivatives according to claim 4, wherein R
1
 is lower-alkyl, such
as ethyl, butyl or isobutyl, lower-alkoxy-lower-alkyl, such as methoxyethyl, lower-alkyl

substituted by benzoyloxy or lower-alkanoyloxy, such as benzoyloxymethyl, acetoxymethyl,
acetoxyethyl or pivaloyloxymethyl, or phenyl.
Acetic acid derivatives according to claim 1, 3, 4 or 5, wherein one of X and
Y is CH and the other is CH or N and/or wherein W
1
 is NH or CH
2
 and/or wherein Q is O
or CH
2
.
Acetic acid derivatives according to any one of claims 1 and 3-6, wherein G
is H, lower-alkyl, such as methyl or ethyl, or lower-alkoxycarbonylamino-lower-alkyl, such

as ethoxycarbonylaminopropyl.
Acetic acid derivatives according to any one of claims 1 and 3-7, wherein M
is 1,4-piperidinylene bonded via the N atom to the keto group, 1,4-phenylene or 1,4-phenylene

substituted by OCH
2
COO-lower-alkyl, such as methoxycarbonylmethoxy.
Acetic acid derivatives according to any one of claims 1 and 3-8, wherein T
is lower-alkoxy, such as methoxy, ethoxy, isopropoxy, isobutoxy, tert-butoxy or hexyloxy,

lower-alkoxy-lower-alkoxy, such as methoxyethoxy, lower-alkenyloxy substituted by COO-lower-alkyl,
such as 2-isobutoxycarbonyl-2-pentenyloxy, lower-alkoxy substituted by

lower-alkyl-COO, such as pivaloyloxymethoxy, lower-alkoxy substituted by lower-alkyl-OCOO,
such as 1-isopropoxycarbonyloxy-ethoxy, cycloalkoxy optionally interrupted by O,

such as tetrahydropyranyloxy, pyridyl bonded via lower-alkyleneoxy, such as 3- or 4-pyridylmethoxy,
or cycloalkyl bonded via lower-alkyleneoxy and optionally interrupted by

NCOO-lower-alkyl, such as 1-tert-butoxycarbonyl-3 or 4-piperidylmethoxy.
Acetic acid derivatives according to any one of claims 1-9 from the following
group:


Ethyl (S)-4-[2-[4-[imino-2-(methoxy-ethoxycarbonylamino)-methyl]-benzoylamino]
-propionyl]-phenoxyacetate,
ethyl (Z)-(R,S)-4-[2-[4-[amino-hydroxyimino-methyl]-benzoylamino]
-propionyl]-phenoxyacetate,
tetrahydropyran-4-yl (S)-4- [2-[4-(ethoxycarbonylamino-imino-methyl)-benzoylamino]-propionyl]
-phenoxyacetate,
ethyl (Z)-(R,S)-4-[2-[4-[amino-ethoxycarbonyloximino-methyl]-benzoylamino]
-propionyl]-phenoxyacetate,
ethyl (S)-4-[2-[4-(imino-phenoxycarbonylamino-methyl)-benzoylamino]-propionyl]
-phenoxyacetate, 
2-methoxy-ethyl (S)-4-[2-[4-[imino-(2-methoxyethoxy-carbonylamino)-methyl]-benzoylamino]
-propionyl]-phenoxyacetate,
ethyl (Z)-(S)-4-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]
-phenoxyacetate,
isopropyl (E/Z)-(S)-1-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-propionyl]
-piperidin-4-yloxyacetate,
isopropyl (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]
-piperidin-4-yloxyacetate,
isopropyl [1-[4-[4-(ethoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]
-piperidin-4-yloxy]-acetate,
isopropyl (RS)-[1-[4-[4-(isobutoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]
-piperidin-4-yloxy]-acetate

and especially
ethyl (E/Z)-(S)-1-[2- [4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]
-piperidin-4-yloxyacetate.
Acetic acid derivatives according to any one of claims 1 and 3-9 from the
following group:


(R/S)-1-Isopropoxycarbonyloxy-ethyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]
-piperidin-4-yloxy]acetate,
pyridin-3-ylmethyl (R)-(E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]
-piperidin-4-yloxy]-acetate,
pyridin-4-ylmethyl (R)-(E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]
-piperidin-4-yloxy]-acetate,
tert-butyl (E)- or (Z)-(RS)-3-[1-[(R)-4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]
-piperidin-4-yloxyacetoxymethyl]-piperidine-1-carboxylate,
ethyl (R)-[1- [4-[4-(benzoyloxymethoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]
-piperidin-4-yloxy]-acetate,
ethyl (R)-[1-[4-[4-(imino-pivaloyloxymethoxycarbonylamino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]
-piperidin-4-yloxy]-acetate,
tert-butyl (E)- or (Z)-(R)-4-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]
-piperidin-4-yloxyacetoxymethyl]-piperidine-1-carboxylate,
ethyl (S)- [4-[2-[4-[(2-acetoxy-ethoxy-carbonylimino)-amino-methyl]-benzoylamino]
-propionyl]-phenoxy]
-acetate.
Acetic acid derivatives according to claim 1, wherein L is a group L
1
 in
which A is a group A
3
, namely of the formula 

wherein E
1
, m, n, D, W
1
, G, Q and T have the same significance as in claim
1 and M is 1,4-phenylene.
Acetic acid derivatives according to claim 1 or 12, wherein E
1
 is H, OH or
C(O)OR
1
, m and n are the number 2 and/or D and Q are O and/or W
1
 is NH and/or G is
lower-alkyl, such as methyl, and/or T is lower-alkoxy, such as ethoxy.
Acetic acid derivatives according to claim 13, wherein E
1
 is lower-alkanoyloxy-lower-alkoxycarbonyl,
such as acetoxymethoxycarbonyl.
The compound according to claim 12, 13 or 14, acetoxymethyl (S)-4-[2-(4-ethoxycarbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoylmethoxy]-piperidine-1-carboxylate.
Acetic acid derivatives according to claim 1, wherein L is a group L
1
 in
which A is a group A
2
, namely of the formula

wherein E
1
, X, Y, W
1
, G, M, Q and T have the same significance as in claim 1,
especially wherein Q is O and T is OH or lower-alkoxy.
Acetic acid derivatives according to claim 1, wherein L is a group L
1
 in
which A is a group A
4
, namely of the formula

wherein E
1
, p, q, W
1
, G, M, Q and T have the same significance as in claim 1,
especially wherein M is 1,4-phenylene, Q is O and T is lower-alkoxy.
Acetic acid derivatives according to claim 1, wherein L is a group L
2
 in
which A is a group A
1
, namely of the formula

wherein E
1
, E
2
, X, Y, W
2
, G, M, Q and T have the same significance as in claim
1, especially wherein M is 1,4-piperidinylene bonded via the N atom to the keto

group, Q is O and T is lower-alkoxy.
Acetic acid derivatives according to claim 1, wherein L is a group L
3
 in
which A is a group A
1
, namely of the formula

wherein E
1
, E
2
, X, Y, G, M, Q and T have the same significance as in claim 1,
especially wherein M is 1,4-piperidinylene bonded via the N atom to the keto

group, Q is O and T is lower-alkoxy.
Acetic acid derivatives according to claim 1, wherein L is a group L
4
 in
which A is a group A
1
, namely of the formula

wherein E
1
, E
2
, X, Y, G, M, Q and T have the same significance as in claim 1,
especially wherein M is 1,4-phenylene, Q is O and T is lower-alkoxy.
Acetic acid derivatives according to claim 1, wherein L is a group L
5
, namely
of the formula


wherein E
1
, E
2
, G, M, Q and T have the same significance as in claim 1, especially
wherein M is 1,4-piperidinylene bonded via the N atom to the keto group, Q is O

and T is lower-alkoxy.
Compounds acccording to any one of claims 1-21 for use as pharmaceutically
active substances.
A process for the manufacture of the compounds according to claim 1,
characterized by


a) cleaving the protected amino or amidino group in a compound of the formula

wherein L
o
 is a group of one of formulae L
10
 to L
50
in which A
o
 is a group A containing a protected amino or amidino group, and A,
W
1
, W
2
, G, M, Q and T have the same significance as in claim 1 and A
01
 is a
protected amidino group,

or
b) converting the free amidino group in a compound of formula III

wherein L
100
 is a group of one of formulae L
101
 to L
501
in which A
101
 is a group A containing a free amidino group and A, W
1
, W
2
, G, M, Q
and T have the same significance as in claim 1,
or in a salt thereof into an amidino group substituted by a group E
1
 or E
2
, or
c) converting the cyano group present in L
11
 in a compound of formula IV 

wherein L
11
 is a group of one of formulae L
111
 to L
115
in which X, Y, W
1
, W
2
, G, M, Q and T have the same significance as in claim 1,
into an amidino group optionally substituted by E
1
 or E
2
, or
d) reacting an amine of the formula

wherein R
2
 is H, lower-alkyl or lower-alkoxy-lower-alkyl and G, M, Q and T have
the same significance as in claim 1,

with an acid A-COOH or a functional derivative thereof, or 
e) if desired, functionally modifying a reactive group present in a compound of
formula I, and
f) if desired, converting a compound of formula I into a physiologically compatible
salt or converting a salt of a compound of formula I into the free acid or base.
Pharmaceutical preparations, especially for the treatment or prophylaxis of
illnesses which are caused by the binding of adhesive proteins to blood platelets as well as

by blood platelet aggregation and cell-cell adhesion, containing a compound according to
any one of claims 1-21 as the active substance.
The use of a compound according to any one of claims 1-21 for the
production of medicaments for the treatment or prophylaxis of illnesses which are caused

by the binding of adhesive proteins to blood platelets as well as by blood platelet
aggregation and cell-cell adhesion, especially for the treatment or prophylaxis of blood

platelet thrombi, thrombosis, stroke, cardiac infarct, inflammation, arteriosclerosis or
osteoporosis, or as antitumour medicaments or as medicaments for wound healing.
The acetic acid derivatives according to any one of claims 1-9,

ethyl (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]
-piperidin-4-yloxyacetate.
</CLAIMS>
</TEXT>
</DOC>
